Overview Dividends

(LMAT) LeMaitre Vascular - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5255582018

Vascular Grafts, Endarterectomy Kits, Shunts, Bypass Catheters, Valvulotomes

LMAT EPS (Earnings per Share)

EPS Growth (3Y CAGR): -50.97%
EPS Trend (3Y Correlation): 15.6%

LMAT Revenue

Revenue Growth (3Y CAGR): 19.86%
Revenue Trend (3Y Correlation): 95.6%

Description: LMAT LeMaitre Vascular August 10, 2025

LeMaitre Vascular Inc, listed on NASDAQ under the ticker symbol LMAT, is a US-based company operating in the Health Care Equipment sub-industry. To evaluate its performance, we need to examine key financial metrics and drivers.

The companys market capitalization stands at approximately $1.9 billion, with a price-to-earnings (P/E) ratio of 41.15 and a forward P/E of 37.31, indicating a relatively high valuation compared to its current earnings. The return on equity (RoE) is 13.53%, suggesting a decent return for shareholders. To further assess its financial health, we should consider revenue growth, profit margins, and cash flow generation.

Key economic drivers for LeMaitre Vascular include the demand for vascular surgery products and the overall growth of the healthcare industry. The companys performance is likely influenced by factors such as the prevalence of vascular diseases, advancements in medical technology, and the competitive landscape. To gauge its competitive position, we can analyze metrics such as market share, product innovation, and sales and marketing expenses as a percentage of revenue.

From a trading perspective, its essential to monitor KPIs such as trading volume, liquidity, and volatility. With an average trading volume of 117,735 shares, LMAT appears to have a reasonable level of liquidity. The stocks beta of 0.785 suggests relatively lower volatility compared to the broader market. To identify potential trading opportunities, we can analyze trends, support and resistance levels, and other technical indicators.

LMAT Stock Overview

Market Cap in USD	2,019m
Sub-Industry	Health Care Equipment
IPO / Inception	2006-10-19

LMAT Stock Ratings

Growth Rating	38.1%
Fundamental	71.4%
Dividend Rating	66.9%
Return 12m vs S&P 500	-25.8%
Analyst Rating	3.73 of 5

LMAT Dividends

Dividend Yield 12m	0.88%
Yield on Cost 5y	2.15%
Annual Growth 5y	13.92%
Payout Consistency	100.0%
Payout Ratio	36.9%

LMAT Growth Ratios

Growth Correlation 3m	-75.3%
Growth Correlation 12m	-39.9%
Growth Correlation 5y	82.3%
CAGR 5y	26.94%
CAGR/Max DD 3y (Calmar Ratio)	0.81
CAGR/Mean DD 3y (Pain Ratio)	2.56
Sharpe Ratio 12m	0.42
Alpha	-24.68
Beta	0.766
Volatility	31.98%
Current Volume	163.2k
Average Volume 20d	108.7k
Stop Loss	83.6 (-3.1%)
Signal	-0.16

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (47.1m TTM) > 0 and > 6% of Revenue (6% = 14.1m TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA 0.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 170.2% (prev 91.12%; Δ 79.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.10 (>3.0%) and CFO 58.8m > Net Income 47.1m (YES >=105%, WARN >=100%)

Net Debt (158.7m) to EBITDA (75.8m) ratio: 2.09 <= 3.0 (WARN <= 3.5)

Current Ratio 13.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (22.9m) change vs 12m ago 0.73% (target <= -2.0% for YES)

Gross Margin 69.11% (prev 67.70%; Δ 1.41pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 49.89% (prev 56.63%; Δ -6.74pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 23.55 (EBITDA TTM 75.8m / Interest Expense TTM 2.79m) >= 6 (WARN >= 3)

Altman Z'' 7.16

(A) 0.69 = (Total Current Assets 430.1m - Total Current Liabilities 30.8m) / Total Assets 577.6m

(B) 0.28 = Retained Earnings (Balance) 160.8m / Total Assets 577.6m

(D) 0.74 = Book Value of Equity 158.1m / Total Liabilities 214.9m

Total Rating: 7.16 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 71.39

1. Piotroski 5.0pt = 0.0

2. FCF Yield 2.77% = 1.39

3. FCF Margin 22.30% = 5.57

4. Debt/Equity 0.51 = 2.37

5. Debt/Ebitda 2.09 = -0.18

6. ROIC - WACC (= 2.52)% = 3.15

7. RoE 13.67% = 1.14

8. Rev. Trend 95.60% = 7.17

9. EPS Trend 15.64% = 0.78

What is the price of LMAT shares?

As of November 06, 2025, the stock is trading at USD 86.27 with a total of 163,225 shares traded.
Over the past week, the price has changed by -2.93%, over one month by -1.39%, over three months by +0.99% and over the past year by -11.79%.

Is LeMaitre Vascular a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, LeMaitre Vascular (NASDAQ:LMAT) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 71.39 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LMAT is around 91.37 USD . This means that LMAT is currently overvalued and has a potential downside of 5.91%.

Is LMAT a buy, sell or hold?

LeMaitre Vascular has received a consensus analysts rating of 3.73. Therefor, it is recommend to hold LMAT.

Strong Buy: 3
Buy: 2
Hold: 6
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the LMAT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	104.6	21.3%
Analysts Target Price	104.6	21.3%
ValueRay Target Price	101.6	17.7%

LMAT Fundamental Data Overview October 27, 2025

Market Cap USD = 2.02b (2.02b USD * 1.0 USD.USD)
P/E Trailing = 43.5171
P/E Forward = 34.8432
P/S = 8.6068
P/B = 5.4221
P/EG = 2.0522
Beta = 0.766
Revenue TTM = 234.6m USD
EBIT TTM = 65.8m USD
EBITDA TTM = 75.8m USD
Long Term Debt = 168.2m USD (from longTermDebt, last quarter)
Short Term Debt = 2.83m USD (from shortTermDebt, last quarter)
Debt = 185.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 158.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.89b USD (2.02b + Debt 185.9m - CCE 319.5m)
Interest Coverage Ratio = 23.55 (Ebit TTM 65.8m / Interest Expense TTM 2.79m)
FCF Yield = 2.77% (FCF TTM 52.3m / Enterprise Value 1.89b)
FCF Margin = 22.30% (FCF TTM 52.3m / Revenue TTM 234.6m)
Net Margin = 20.08% (Net Income TTM 47.1m / Revenue TTM 234.6m)
Gross Margin = 69.11% ((Revenue TTM 234.6m - Cost of Revenue TTM 72.5m) / Revenue TTM)
Gross Margin QoQ = 70.02% (prev 69.18%)
Tobins Q-Ratio = 3.27 (Enterprise Value 1.89b / Total Assets 577.6m)
Interest Expense / Debt = 0.70% (Interest Expense 1.30m / Debt 185.9m)
Taxrate = 23.75% (4.29m / 18.1m)
NOPAT = 50.2m (EBIT 65.8m * (1 - 23.75%))
Current Ratio = 13.96 (Total Current Assets 430.1m / Total Current Liabilities 30.8m)
Debt / Equity = 0.51 (Debt 185.9m / totalStockholderEquity, last quarter 362.7m)
Debt / EBITDA = 2.09 (Net Debt 158.7m / EBITDA 75.8m)
Debt / FCF = 3.03 (Net Debt 158.7m / FCF TTM 52.3m)
Total Stockholder Equity = 344.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.16% (Net Income 47.1m / Total Assets 577.6m)
RoE = 13.67% (Net Income TTM 47.1m / Total Stockholder Equity 344.7m)
RoCE = 12.83% (EBIT 65.8m / Capital Employed (Equity 344.7m + L.T.Debt 168.2m))
RoIC = 10.66% (NOPAT 50.2m / Invested Capital 470.6m)
WACC = 8.14% (E(2.02b)/V(2.21b) * Re(8.84%) + D(185.9m)/V(2.21b) * Rd(0.70%) * (1-Tc(0.24)))
Discount Rate = 8.84% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.96%
[DCF Debug] Terminal Value 78.90% ; FCFE base≈44.1m ; Y1≈54.4m ; Y5≈92.7m
Fair Price DCF = 59.96 (DCF Value 1.36b / Shares Outstanding 22.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 15.64 | EPS CAGR: -50.97% | SUE: -4.0 | # QB: 0
Revenue Correlation: 95.60 | Revenue CAGR: 19.86% | SUE: 1.61 | # QB: 2

Additional Sources for LMAT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle